Beijing Wantai Biological Pharmacy Enterprise Co.: Higher 9M revenue could not offset operating pressures and a RMB 230.8m attributable net loss

What happened

Beijing Wantai Biological Pharmacy's nine-month revenue rose 8.29% from a year earlier, but it still posted an attributable net loss of RMB 230.8m. Higher nine-valent HPV vaccine revenue lifted gross profit, while marketing costs, currency losses and vaccine inventory write-downs weighed on results.

Confirmed

Global impact / market context

Revenue growth alone did not cover rising marketing spending, currency losses and inventory write-downs, which are reductions in the recorded value of unsold vaccine stock. That combination pushed the company to a net loss, showing that sales gains can be erased by cost and inventory pressures.

Analyst inference

Investors may focus on whether the nine-valent HPV vaccine, which means a vaccine designed to protect against nine strains of the virus, can keep driving sales. The loss highlights that higher revenue does not automatically mean profit when costs and inventory charges rise.

Analyst inference

What to watch

1. Nine-month revenue rose 8.29% year over year, and the attributable net loss was RMB 230.8m, a factual result investors can compare with the next reported period. Confirmed
2. Watch whether management cuts marketing costs or reduces vaccine inventory write-downs, since either change would need to be stated by the company before it can be treated as fact. Proposed
3. Track currency losses and vaccine inventory write-downs in future reports, because if they persist they could keep offsetting gross profit gains from higher nine-valent HPV vaccine revenue. Analyst inference

Evidence

• Original source link unavailable